Research Progress of HGF/MET Signaling Pathway in EGFR-TKI Resistance in Non-small Cell Lung Cancer
10.3779/j.issn.1009-3419.2014.10.08
- VernacularTitle:HGF/MET信号通路在非小细胞肺癌EGFR-TKI耐药性中的研究进展
- Author:
SONG SHILONG
1
;
BI MINGHONG
Author Information
1. 蚌埠医学院第一附属医院肿瘤内科
- Keywords:
HGF;
MET;
Lung neoplasms;
EGFR-TKI;
Resistance
- From:
Chinese Journal of Lung Cancer
2014;(10):755-759
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is one of the most common malignant tumors of the world, and non-small cell lung cancer (NSCLC) makes up about 80%. hTe hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (MET) signal pathway has pleiotropic effects on many biological processes. However, aberrant HGF/MET signal pathway activation has been observed in many tumor types, and promotes cellular proliferation and metastasis via growth factor receptors and other oncogenic receptor pathways. In recent years, aberrant HGF/MET signal pathway activation has been considered a key step of resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy. hTis review addresses how aberrant HGF/MET signal pathway activation being associated with drug resistance to EGFR-TKI therapy in NSCLC patients.
